DOW JONES21,636.78-915.39 -4.06%
S&P 5002,541.47-88.60 -3.37%
NASDAQ7,502.38-295.16 -3.79%

Bernstein Upgrades Jazz Pharmaceuticals to Outperform, Lowers Price Target to $166

Bernstein analyst Ronny Gal upgrades Jazz Pharmaceuticals (NASDAQ:JAZZ) from Market Perform to Outperform and lowers the price target from $175 to $166.

Benzinga · 03/12/2020 10:33

Bernstein analyst Ronny Gal upgrades Jazz Pharmaceuticals (NASDAQ:JAZZ) from Market Perform to Outperform and lowers the price target from $175 to $166.